This legislation establishes an Office of Novel Therapeutics within the Veterans Health Administration (VHA) under the Office of the Under Secretary for Health. This new office will serve as the primary coordinating authority for all matters related to emerging and novel therapeutic interventions, focusing on developing national policy, guidance, and clinical standards for their evaluation, research, and potential implementation. A key aspect is the development of a national clinical model for intensive therapeutic interventions, including structured preparation, monitored administration, and post-administration integration, especially for mental health conditions affecting veterans. The Office of Novel Therapeutics is tasked with developing implementation-readiness plans, conducting workforce assessments, and establishing national training and credentialing standards for clinicians. It will also oversee a Clinical Implementation Program to evaluate the effectiveness, feasibility, and safety of these interventions, prioritizing conditions such as post-traumatic stress disorder and depression. The bill further authorizes the designation of centers of excellence for novel therapeutics to lead research, training, and implementation, and establishes a Veteran Advisory Committee to provide crucial input on patient safety, informed consent, and patient-centered care design. The Secretary is required to coordinate with other federal agencies and submit annual reports to Congress on research activities, clinical outcomes, safety, and implementation challenges.